Towards the discovery of novel T-type calcium channel blockers

Bibliography

• HUGUENARD JR: Low-threshold calcium currents in central nervous system neurons. Ann. Rev. Physiol. (1996) 58:329-348.
   PubMed Web of Science ®Google Scholar
• PEREZ-REYES E: Molecular physiology of low-voltage-activated T-type calcium channels. Physiol. Rev. (2003) 83:117-161.
   PubMed Web of Science ®Google Scholar
• YUNKER AM, MCENERY MW: Low-voltage-activated (‘T-Type’) calcium channels in review. J. Bioenerg. Biomembr. (2003) 35:533-575.
   PubMed Web of Science ®Google Scholar
• LACINOVA L: Voltage-dependent calcium channels. Gen. Physiol. Biophys. (2005) 24(Suppl. 1):1-78.
   PubMedGoogle Scholar
• NILIUS B, TALAVERA K, VERKHRATSKY A: T-type calcium channels: the never ending story. Cell Calcium (2006) 40:81-88.
   PubMedGoogle Scholar
• KIM D, SONG I, KEUM S et al.: Lack of the burst firing of thalamocortical relay neurons and resistance to absence seizures in mice lacking α1G T-type Ca2+ channels. Neuron (2001) 31:35-45.
   PubMed Web of Science ®Google Scholar
• CHEN CC, LAMPING KG, NUNO DW et al.: Abnormal coronary function in mice deficient in α1H T-type Ca2+ channels. Science (2003) 302:1416-1418.
   PubMed Web of Science ®Google Scholar
• KIM D, PARK D, CHOI S, LEE S, SUN M, KIM C, SHIN HS: Thalamic control of visceral nociception mediated by T-type Ca2+ channels. Science (2003) 302:117-119.
   PubMed Web of Science ®Google Scholar
• ANDERSON MP, MOCHIZUKI T, XIE J et al.: Thalamic CaV3.1 T-type Ca2+ channel plays a crucial role in stabilizing sleep. Proc. Natl. Acad. Sci. USA (2005) 102:1743-1748.
   PubMed Web of Science ®Google Scholar
• MANGONI ME, TRABOULSIE A, LEONI AL et al.: Bradycardia and slowing of the atrioventricular conduction in mice lacking CaV3.1/α1G T-type calcium channels. Circ. Res. (2006) 98:1422-1430.
   PubMed Web of Science ®Google Scholar
• MISHRA SK, HERMSMEYER K: Selective inhibition of T-type Ca2+ channels by Ro 40-5967. Circ. Res. (1994) 75:144-148.
   PubMed Web of Science ®Google Scholar
• CLOZEL JP, ERTEL EA, ERTEL SI: Discovery and main pharmacological properties of mibefradil (Ro 40-5967), the first selective T-type calcium channel blocker. J. Hypertens. (1997) 15(Suppl.)S17-S25.
   Google Scholar
• LACINOVA L: Pharmacology of recombinant low-voltage activated calcium channels. Curr. Drug Targets CNS Neurol. Disord. (2004) 3:105-111.
   PubMedGoogle Scholar
• BEEDLE AM, HAMID J, ZAMPONI GW: Inhibition of transiently expressed low- and high-voltage-activated calcium channels by trivalent metal cations. J. Membr. Biol. (2002) 187:225-238.
   PubMed Web of Science ®Google Scholar
• LEE JH, GOMORA JC, CRIBBS LL, PEREZ-REYES E: Nickel block of three cloned T-type calcium channels: low concentrations selectively block α1H. Biophys. J. (1999) 77:3034-3042.
   PubMed Web of Science ®Google Scholar
• ERTEL SI, ERTEL EA, CLOZEL JP: T-type Ca2+ channels and pharmacological blockade: potential pathophysiological relevance. Cardiovasc. Drugs Ther. (1997) 11:723-739.
   PubMedGoogle Scholar
• PO AL, ZHANG WY: What lessons can be learnt from withdrawal of mibefradil from the market? Lancet (1998) 351:1829-1830.
   PubMed Web of Science ®Google Scholar
• LEURANGUER V, MANGONI ME, NARGEOT J, RICHARD S: Inhibition of T-type and L-type calcium channels by mibefradil: physiologic and pharmacologic bases of cardiovascular effects. J. Cardiovasc. Pharmacol. (2001) 37:649-661.
   PubMedGoogle Scholar
• MOOSMANG S, HAIDER N, BRUDERL B, WELLING A, HOFMANN F: Antihypertensive effects of the putative T-type calcium channel antagonist mibefradil are mediated by the L-type calcium channel CaV1.2. Circ. Res. (2006) 98:105-110.
   PubMedGoogle Scholar
• GACKIERE F, BIDAUX G, LORY P, PREVARSKAYA N, MARIOT P: A role for voltage gated T-type calcium channels in mediating ‘capacitative’ calcium entry? Cell Calcium (2006) 39:357-366.
   PubMedGoogle Scholar
• TANG CM, PRESSER F, MORAD M: Amiloride selectively blocks the low threshold (T) calcium channel. Science (1988) 240:213-215.
   PubMed Web of Science ®Google Scholar
• TYTGAT J, VEREECKE J, CARMELIET E: Mechanism of cardiac T-type Ca channel blockade by amiloride. J. Pharmacol. Exp. Ther. (1990) 254:546-551.
   PubMed Web of Science ®Google Scholar
• WILLIAMS ME, WASHBURN MS, HANS M et al.: Structure and functional characterization of a novel human low-voltage activated calcium channel. J. Neurochem. (1999) 72:791-799.
   PubMedGoogle Scholar
• MONTEIL A, CHEMIN J, BOURINET E, MENNESSIER G, LORY P, NARGEOT J : Molecular and functional properties of the human α1G subunit that forms T-type calcium channels. J. Biol. Chem. (2000) 275:6090-6100.
   PubMed Web of Science ®Google Scholar
• TODOROVIC SM, LINGLE CJ: Pharmacological properties of T-type Ca2+ current in adult rat sensory neurons: effects of anticonvulsant and anesthetic agents. J. Neurophysiol. (1998) 79:240-252.
   PubMed Web of Science ®Google Scholar
• ARNOULT C, VILLAZ M, FLORMAN HM: Pharmacological properties of the T-type Ca2+ current of mouse spermatogenic cells. Mol. Pharmacol. (1998) 53:1104-1111.
   PubMedGoogle Scholar
• BERTHIER C, MONTEIL A, LORY P, STRUBE C: α1H mRNA in single skeletal muscle fibres accounts for T-type calcium current transient expression during fetal development in mice. J. Physiol. (2002) 539:681-691.
   PubMed Web of Science ®Google Scholar
• AKAIKE N: T-type calcium channel in mammalian CNS neurones. Comp. Biochem. Physiol. C. (1991) 98:31-40.
   PubMedGoogle Scholar
• SANTI CM, CAYABYAB FS, SUTTON KG et al.: Differential inhibition of T-type calcium channels by neuroleptics. J. Neurosci. (2002) 22:396-403.
   PubMed Web of Science ®Google Scholar
• RICHELSON E, SOUDER T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. (2000) 68:29-39.
   PubMed Web of Science ®Google Scholar
• HUGUENARD JR: Block of T -Type Ca2+ channels is an important action of succinimide antiabsence drugs. Epilepsy Curr. (2002) 2:49-52.
   PubMedGoogle Scholar
• CRUNELLI V, LERESCHE N: Block of thalamic T-Type Ca2+ channels by ethosuximide is not the whole story. Epilepsy Curr. (2002) 2:53-56.
   PubMedGoogle Scholar
• HAINSWORTH AH, MCNAUGHTON NC, PEREVERZEV A, SCHNEIDER T, RANDALL AD: Actions of sipatrigine, 202W92 and lamotrigine on R-type and T-type Ca2+ channel currents. Eur. J. Pharmacol. (2003) 467:77-80.
   PubMed Web of Science ®Google Scholar
• TODOROVIC SM, JEVTOVIC-TODOROVIC V, MENNERICK S, PEREZ-REYES E, ZORUMSKI CF: CaV3.2 channel is a molecular substrate for inhibition of T-type calcium currents in rat sensory neurons by nitrous oxide. Mol. Pharmacol. (2001) 60:603-610.
   PubMed Web of Science ®Google Scholar
• TODOROVIC SM, PEREZ-REYES E, LINGLE CJ: Anticonvulsants but not general anesthetics have differential blocking effects on different T-type current variants. Mol. Pharmacol. (2000) 58:98-108.
   PubMed Web of Science ®Google Scholar
• TRABOULSIE A, CHEMIN J, KUPFER E, NARGEOT J, LORY P: T-type calcium channels are inhibited by fluoxetine and its metabolite norfluoxetine. Mol. Pharmacol. (2006) 69:1963-1968.
   PubMed Web of Science ®Google Scholar
• CHUANG RS, JAFFE H, CRIBBS L, PEREZ-REYES E, SWARTZ KJ: Inhibition of T-type voltage-gated calcium channels by a new scorpion toxin. Nat. Neurosci. (1998) 1:668-674.
   PubMed Web of Science ®Google Scholar
• SIDACH SS, MINTZ IM: Kurtoxin, a gating modifier of neuronal high- and low-threshold ca channels. J. Neurosci. (2002) 22:2023-2034.
   PubMed Web of Science ®Google Scholar
• OLAMENDI-PORTUGAL T, GARCIA BI, LOPEZ-GONZALEZ I et al.: Two new scorpion toxins that target voltage-gated Ca2+ and Na+ channels. Biochem. Biophys. Res. Commun. (2002) 299:562-568.
   PubMed Web of Science ®Google Scholar
• DI MARZO V, DE PETROCELLIS L, BISOGNO T: The biosynthesis, fate and pharmacological properties of endocannabinoids. Handb. Exp. Pharmacol. (2005) 168:147-185.
   PubMedGoogle Scholar
• CHEMIN J, MONTEIL A, PEREZ-REYES E, NARGEOT J, LORY P: Direct inhibition of T-type calcium channels by the endogenous cannabinoid anandamide. EMBO J. (2001) 20:7033-7040.
   PubMedGoogle Scholar
• CHEMIN J, NARGEOT J, LORY P: Chemical determinants involved in anandamide-induced inhibition of T-type calcium channels. J. Biol. Chem. (2007) 282:2314-2323.
   PubMedGoogle Scholar
• DANTHI SJ, ENYEART JA, ENYEART JJ: Modulation of native T-type calcium channels by omega-3 fatty acids. Biochem. Biophys. Res. Commun. (2005) 327:485-493.
   PubMed Web of Science ®Google Scholar
• TALAVERA K, STAES M, JANSSENS A, DROOGMANS G, NILIUS B : Mechanism of arachidonic acid modulation of the T-type Ca2+ channel α1G. J. Gen. Physiol. (2004) 124:225-238.
   PubMedGoogle Scholar
• MATHIE A, SUTTON GL, CLARKE CE, VEALE EL: Zinc and copper: pharmacological probes and endogenous modulators of neuronal excitability. Pharmacol. Ther. (2006) 111:567-583.
   PubMed Web of Science ®Google Scholar
• BUSSELBERG D, MICHAEL D, EVANS ML, CARPENTER DO, HAAS HL: Zinc (Zn2+) blocks voltage gated calcium channels in cultured rat dorsal root ganglion cells. Brain Res. (1992) 593:77-81.
   PubMedGoogle Scholar
• JEONG SW, PARK BG, PARK JY, LEE JW, LEE JH: Divalent metals differentially block cloned T-type calcium channels. Neuroreport (2003) 14:1537-1540.
   PubMedGoogle Scholar
• TRABOULSIE A, CHEMIN J, CHEVALIER M, QUIGNARD JF, NARGEOT J, LORY P : Subunit-specific modulation of T-type calcium channels by zinc. J. Physiol. (2007) 578:159-171.
   PubMed Web of Science ®Google Scholar
• DODDAREDDY MR, JUNG HK, LEE JY et al.: First pharmacophoric hypothesis for T-type calcium channel blockers. Bioorg. Med. Chem. (2004) 12:1605-1611.
   PubMed Web of Science ®Google Scholar
• CHOI JY, SEO HN, LEE MJ et al.: Synthesis and biological evaluation of novel T-type calcium channel blockers. Bioorg. Med. Chem. Lett. (2007) 17:471-475.
   PubMedGoogle Scholar
• DODDAREDDY MR, CHOO H, CHO YS et al.: 3D pharmacophore based virtual screening of T-type calcium channel blockers. Bioorg Med Chem (2007) 15:1091-1105.
   PubMed Web of Science ®Google Scholar
• PARK JH, CHOI JK, LEE E et al.: Lead discovery and optimization of T-type calcium channel blockers. Bioorg. Med. Chem. (2007) 15:1409-1419.
   PubMedGoogle Scholar
• HUANG L, KEYSER BM, TAGMOSE TM et al.: NNC 55-0396 [(1S,2S)-2-(2-(N-[(3-benzimidazol-2-yl) propyl]-N-methylamino)ethyl)-6-fluo ro-1,2,3,4-tetrahydro-1-isopropyl-2-naphtyl cyclopropanecarboxylate dihydrochloride]: a new selective inhibitor of T-type calcium channels. J. Pharmacol. Exp. Ther. (2004) 309:193-199.
   PubMedGoogle Scholar
• AKAIKE N, KOSTYUK PG, OSIPCHUK YV: Dihydropyridine-sensitive low-threshold calcium channels in isolated rat hypothalamic neurones. J. Physiol. (1989) 412:181-195.
   PubMed Web of Science ®Google Scholar
• GODFRAIND T: Calcium-channel modulators for cardiovascular disease. Expert Opin. Emerg. Drugs (2006) 11:49-73.
   PubMedGoogle Scholar
• KUMAR PP, STOTZ SC, PARAMASHIVAPPA R, BEEDLE AM, ZAMPONI GW, RAO AS: Synthesis and evaluation of a new class of nifedipine analogs with T-type calcium channel blocking activity. Mol. Pharmacol. (2002) 61:649-658.
   PubMed Web of Science ®Google Scholar
• TANAKA H, KOMIKADO C, SHIMADA H et al.: The R(-)-enantiomer of efonidipine blocks T-type but not L-type calcium current in guinea pig ventricular myocardium. J. Pharmacol. Sci. (2004) 96:499-501.
   PubMed Web of Science ®Google Scholar
• FURUKAWA T, NUKADA T, MIURA R et al.: Differential blocking action of dihydropyridine Ca2+ antagonists on a T-type Ca2+ channel (α1G) expressed in Xenopus oocytes. J. Cardiovasc. Pharmacol. (2005) 45:241-246.
   PubMed Web of Science ®Google Scholar
• MCGIVERN JG: Pharmacology and drug discovery for T-type calcium channels. CNS Neurol. Disord. Drug Targets (2006) 5:587-603.
   PubMedGoogle Scholar
• BIDAUD I, MEZGHRANI A, SWAYNE LA, MONTEIL A, LORY P: Voltage-gated calcium channels in genetic diseases. Biochim. Biophys. Acta (2006) 1763:1169-1174.
   PubMed Web of Science ®Google Scholar
• CHEMIN J, TRABOULSIE A, LORY P: Molecular pathways underlying the modulation of T-type calcium channels by neurotransmitters and hormones. Cell Calcium (2006) 40:121-134.
   PubMed Web of Science ®Google Scholar